PositiveID Chairman and CEO Interviewed on The RedChip Money Report


DELRAY BEACH, Fla., July 01, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation (OTCQB:PSID), a life sciences company focused on detection and diagnostics, is pleased to announce its Chairman and CEO, William J. Caragol, was recently interviewed on The RedChip Money Report television program. The interview will air Sunday, July 3, at 11:00 a.m. ET on Newsmax TV, available in 40 million homes via DIRECTV, DISH, and Verizon FiOS.

To view the interview segment, please visit: https://youtu.be/BvdLOtLwcCg

In the interview, Caragol discusses PositiveID’s molecular diagnostics business including its Firefly Dx real-time pathogen detection system; E-N-G Mobile Systems, its mobile labs business; and Thermomedics, its medical device business, which markets the Caregiver® FDA-cleared, non-contact thermometer. 

The RedChip Money Report delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. The show is hosted by Dave Gentry, a leading authority on small-cap stocks and the author of Small Stocks, Big Money, published by Wiley Finance. Gentry has made multiple guest appearances on both CNBC and Fox Business News.

About PositiveID

PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the specialty vehicle market, with a focus on mobile labs. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on TwitterFacebook or LinkedIn.

Safe Harbor Statement

Statements about PositiveID's future expectations constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to grow its mobile labs business; the Company’s ability to target the biodefense market, the healthcare market, as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 12, 2016, and 10-Qs filed on May 16, 2016, November 12, 2015, and August 13, 2015, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.


            

Contact Data